Verified Evidence: resolved · Fact Lock: locked · QA: pass
Reports dated October 28, 2026, described a Department of Health and Human Services policy directing the FDA not to take action against specialty pharmacies that sell or compound six unapproved wellness peptides. People familiar with the policy’s development said FDA staff opposed the approach, which was associated with Health Secretary Robert F. Kennedy Jr.

The policy concerns injectable peptides promoted or popular within the wellness industry. The products at issue have not been approved by the FDA as safe and effective, according to the reporting, putting them outside the agency’s normal review framework for authorized medicines.

NPR reported that HHS would allow small compounding pharmacies to make six peptides that have not received FDA approval. PBS NewsHour and Fast Company described the proposed enforcement approach as directing the FDA not to act against specialty pharmacies selling or compounding the substances, which otherwise would be treated as illegal drugs because they had not undergone FDA review for safety and effectiveness.

The PBS NewsHour account identified BPC-157, TB-500 and KPV among the peptides covered by the policy. It did not identify all six substances, so the full list remains unclear.

The initiative was driven almost entirely by HHS and was linked to Kennedy’s department, according to the reporting. People familiar with its development told Fast Company and PBS NewsHour that most FDA scientific staff opposed the policy or proposed changes and had limited input in drafting them. Those people said FDA drug staffers warned that the effort could undermine the agency’s mission of keeping unproven health products off the U.S. market.

The policy represented a change from an earlier approach, according to two people who discussed its development with PBS NewsHour. HHS initially considered an official regulation that would have listed BPC-157 and other peptides as safe for use by compounding pharmacies, but later moved toward instructing the FDA not to enforce its rules against pharmacies that compound the substances. FDA staffers also provided technical assistance, including proposed safeguards such as requiring pharmacies to use peptide ingredients from FDA-registered factories.

Fast Company reported that the policy document had undergone regulatory review at the White House, which it described as typically the final step before publication. PBS NewsHour said a document was posted online on October 28, 2026, but the available reporting does not establish whether that posting constituted final formal publication or made the policy immediately effective.

The reporting therefore establishes the intended enforcement direction and the dispute over FDA scientific input, but not the policy’s exact legal mechanism, effective date or complete list of peptides. The central issue is whether specialty pharmacies would gain broader access to products that have not been reviewed by the FDA for safety and effectiveness.

SOURCES

  1. PBS NewsHourAP report: FDA scientists opposed the Trump administration's move to ease peptides access
  2. Fast CompanyHow FDA scientists opposed the Trump administration’s push for easier access to peptides
  3. MedPage TodayRFK Jr. Eases Access to Unproven Peptides Despite Opposition From FDA Scientists
  4. NPRTrump administration will allow pharmacies to make popular peptides